1 therapeutics 2 3 Supplementary Methods 4 5 1 BGC and drug annotation data collection 6 Host microbes information like biosynthetic gene clusters (BGCs) and their molecular 7 products are downloaded from the Minimum Information about a Biosynthetic Gene cluster 8 (MIBiG) specification (1) (version 1.3), which includes 827 microbes, 1,157 BGCs and 1,157 9
2 2 Calculation of MetaMed entity relationships 25 We constructed a data set containing 1,157 microbe biosynthetic gene clusters (BGCs) as 26 well as their metabolites from MIBiG (1) , and 8,226 drugs obtained from DrugBank (2). We 27 defined a solid similarity score by considering both the molecular structure (5) and 28 perturbation transcriptional expression profiles (6) to connect microbe functions with 29 available drug annotation information. To integrate the structural similarity and transcriptional expression similarity, we obtained the 32 final similarity score of microbe-drug pairs by using the mean of structure similarity and 33 transcriptional expression similarity, or using the structure similarity if the transcriptional 34 expression is not available. 1,193,324 linkages were collected based on the structure 35 similarity and finally 18,090 linkages were curated by considering both structure similarity 36 and transcriptional perturbation profiles similarity.
38
Based on the microbe-drug pairs and drug annotations, the scores of microbes with disease 39 treatment effects or side effects are defined directly as the similarity score of microbe-drug 40 pairs. The score of microbes with the impacts on human immune transition is defined as: To estimate the structural similarity between microbe metabolite and drug, we used the 45 simplified molecular-input line-entry system (SMILES) (7) notation to describe these 46 compounds, and calculated the similarity scores from SMILES notations. The SMILES 47 notations of drugs and microbe metabolites are translated from their common name by 48 Chemspipy (8). The structural similarity between two compounds is calculated as the (6). We processed the whole data sets, which include more than 110,000 59 experiments tested over 8,000 compounds. We collected microbe transcriptional perturbation 60 data by linking microbial metabolites to the LINCS compounds with the same compound 61 names or same compound structures (SMILES notations). Then, we selected the up-regulated To examine the global landscape of the MetaMed, we first filtered the data by microbe-drug 71 pairs similarity score. The low similarity score indicates a low correlation between drugs and 72 microbes, and holds limit clues for identifying the real relationship between drugs and 73 4 microbes. We set the similarity cutoff of 0.6 for drug and microbe relationship for global 74 analysis. Then we annotated the drug with ATC classification system level 1 description. We 75 also categrized the microbe with phylum level. We obtained pairs from 366 microbes and 741 76 drugs in total, including 14 classes of drugs and 9 classes of microbes. By appliying our 77 algorithm QUalitative BIClustering algorithm (11) using the QUBIC R packages (version 78 1.6.4 https://bioconductor.org/packages/release/bioc/html/QUBIC.html), we identified three 79 potential biclusters, and they were visualized with heatmap. According to drug annotation information, we demonstrated the utility of the MetaMed from 83 the following five aspects: meaningful microbe-drug linkings, microbes with disease 84 treatment effects, microbes with side effects, microbes with the impacts on immune transition 85 and finally identification of combination drug usage for disease treatment. We selected the 86 pairs with similarity cutoff over 0.9 for validations.
88
We first validated the predicted metabolite-drug links. Two types of pairs are considered. If 89 the similarity scores of microbe-drug pairs are 1.0, it indicates that these microbes can 90 generate exactly the same drugs as the secondary metabolites. If the similarity score is lower 91 than 1.0 while still maintains high similarity, it indicates that these microbes should have 92 similar therapeutic indications as those of the corresponding drugs. For the first type, we 93 found these microbes are already annotated to produce the corresponding drugs as indicated 94 in DrugBank. For the second type of microbe-drug pairs, we validated them by published 95 literature evidence. For other identifications including microbes with disease treatment effects, microbes with 98 side effects and microbes with the impacts on immune transition, we predicted the microbe 99 impact on human directly. If some of the microbes exist in environment and they cannot 100 survive in gut, we took their metabolites as the compound which may have impacts on human 101 health. Then we validated them by availiable databases or published literature evidence.
103
To validate the combination drug usage, we validated the applications in disease treatment by 104 data obtained from immune checkpoint therapy and Metagenome-wide association studies 105 (MWAS) (12, 13) . First, we combined MetaMed with two recent studies of the association of 106 gut microbes in regulating the efficacy of anti-CTLA-4 and anti-PDL1 cancer therapy (14, 107 15). By investigation of the outgrowth microbes, we identified drugs with the similar 108 functions as the secondary metabolites, and these drugs may be taken as the the potential drug 109 combination for treatments. Next we combined MetaMed with MWAS and obtained raw 110 sequence data (ERP002469) of healthy and T2D samples from MWAS. We processed the 111 sequence data by Metapipe and obtained the abundance of OTUs. The differential OTU
